Total
0
Shares
Source: VIP Gloves
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • VIP Gloves (VIP) receives Australian Therapeutic Goods Administration (TGA) approval for its nitrile gloves
  • The TGA has registered VIP’s nitrile examination and treatment gloves as a class one medical device and has given approval to sell the gloves in Australia
  • This news follows USA Food and Drug Administration and European Union CE Mark approvals
  • VIP is up 7.50 per cent and is trading at 4.3 cents per share at 2:25 pm AEST

VIP Gloves (VIP) has received Australian Therapeutic Goods Administration (TGA) approval for its nitrile gloves.

Nitrile gloves are a synthetic rubber compound as opposed to latex.

The TGA has registered VIP’s nitrile examination and treatment gloves as a class one medical device and has given approval to sell the gloves in Australia.

This news follows USA Food and Drug Administration and European Union CE Mark approvals.

Chairman Joe Wong is pleased to have secured TGA approval.

“We have been advancing distribution agreements for the Australian
market in recent months and, with TGA accreditation now received, these
can be finalised enabling sales to commence in the coming months,” Dr Wong said.

“VIP Gloves continues to expand its international sales footprint to become
a global glove supplier, providing a platform to launch the company’s house
brands as capacity expands in the coming months when the additional two
production lines come online.”

VIP was up 7.50 per cent and was trading at 4.3 cents per share at 2:25 pm AEST.

VIP by the numbers
More From The Market Herald
Danodan Hempworks LLC - Founder, Daniel Stoops

" FijiKava (ASX:FIJ) acquires Danodan Hempworks and US patent

Medicinal kava company FijiKava (ASX:FIJ) completes the acquisition of Danodan Hempworks, including its CBD extraction US…
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) buds cannabis oil distribution agreement in Germany

Little Green Pharma (ASX:LGP) enters a three-year distribution agreement to market its LGP cannabis oils in…

" Recce Pharmaceuticals (ASX:RCE) receives positive safety data from second cohort of Phase I Clinical Trial

Recce Pharmaceuticals (ASX:RCE) has released positive safety data from its second cohort of subjects for its…
Virtus Health (ASX:VRT) - CEO & Managing Director, Kate Munnings

" Virtus Health (ASX:VRT) has non-urgent elective surgeries suspended in NSW & VIC

Virtus Health (ASX:VRT) has had its non-urgent elective surgeries suspended in NSW and Victoria as the…